From Pulse 2.0 · Amit Chowdhry · · 1m
Agilent Acquires Proscia for AI Pathology Expansion
Agilent buys Proscia for up to $270m to boost AI-powered digital pathology tools.
In brief
Agilent buys Proscia for up to $270m to boost AI-powered digital pathology tools. Agilent will acquire Proscia for up to $270 million to expand its AI-enabled digital pathology platform. Originally reported by Pulse 2.0.
Agilent Acquires Proscia
Agilent Technologies agreed to acquire Proscia, a digital pathology software provider, in an all-cash transaction valued at $240 million plus up to $30 million in performance milestones.
Digital Pathology Expansion
The acquisition combines Agilent’s instruments and reagents with Proscia’s software to strengthen its position in the $5 billion pathology market.
Proscia's Platform
Proscia’s software connects slide scanners, lab systems, ai tools, people, and data into a unified digital pathology environment.
Market Reach
Proscia serves over 4,000 labs, hospitals, clinics, and 16 of the world’s 20 largest pharmaceutical companies.
FDA Clearance
Proscia’s platform has received FDA 510(k) clearance for primary diagnosis, enabling ai-driven pathology workflows.
Next Steps
The acquisition will close early in Agilent’s fiscal 2027, integrating Proscia into its Life Sciences and Diagnostics Markets Group.
The one thing
Agilent will acquire Proscia for up to $270 million to expand its AI-enabled digital pathology platform.
